169 related articles for article (PubMed ID: 18513297)
1. Letter: clear margins after the use of imatinib mesylate prior to resection of extensive dermatofibrosarcoma protuberans.
Ortiz AE; Wu JJ; Linden KG
Dermatol Surg; 2008 Aug; 34(8):1151. PubMed ID: 18513297
[No Abstract] [Full Text] [Related]
2. Dermatofibrosarcoma protuberans: a partial response to imatinib therapy.
Mehrany K; Swanson NA; Heinrich MC; Weenig RH; Lee KK; White CR; Devere TS
Dermatol Surg; 2006 Mar; 32(3):456-9. PubMed ID: 16640697
[No Abstract] [Full Text] [Related]
3. Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection.
Rutkowski P; Dębiec-Rychter M; Nowecki Z; Michej W; Symonides M; Ptaszynski K; Ruka W
J Eur Acad Dermatol Venereol; 2011 Mar; 25(3):264-70. PubMed ID: 20569296
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate in the treatment of a large unresectable dermatofibrosarcoma protuberans: a case study.
Savoia P; Ortoncelli M; Quaglino P; Bernengo MG
Dermatol Surg; 2006 Aug; 32(8):1097-102. PubMed ID: 16918576
[No Abstract] [Full Text] [Related]
5. Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp.
Kasper B; Lossignol D; Gil T; Flamen P; De Saint Aubain N; Awada A
Anticancer Drugs; 2006 Nov; 17(10):1223-5. PubMed ID: 17075323
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans.
Mizutani K; Tamada Y; Hara K; Tsuzuki T; Saeki H; Tamaki K; Matsumoto Y
Br J Dermatol; 2004 Jul; 151(1):235-7. PubMed ID: 15270901
[No Abstract] [Full Text] [Related]
7. Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans.
Han A; Chen EH; Niedt G; Sherman W; Ratner D
Arch Dermatol; 2009 Jul; 145(7):792-6. PubMed ID: 19620561
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients.
Kérob D; Porcher R; Vérola O; Dalle S; Maubec E; Aubin F; D'Incan M; Bodokh I; Boulinguez S; Madelaine-Chambrin I; Mathieu-Boue A; Servant JM; de Kerviler E; Janin A; Calvo F; Pedeutour F; Lebbe C
Clin Cancer Res; 2010 Jun; 16(12):3288-95. PubMed ID: 20439456
[TBL] [Abstract][Full Text] [Related]
9. Halo nevi related to treatment with imatinib in a dermatofibrosarcoma protuberans patient.
Fava P; Stroppiana E; Savoia P; Bernengo MG
J Eur Acad Dermatol Venereol; 2010 Feb; 24(2):244-5. PubMed ID: 19694892
[No Abstract] [Full Text] [Related]
10. [Long-term experience with multidisciplinary therapy of twenty-six patients with dermatofibrosarcoma protuberans].
Mátrai Z; Liszkay G; Plotár V; Orosz Z; Székely J; Hitre E; Bartal A; Langmár Z; Bocs K; Rényi Vámos F; Sávolt A; Tóth L
Orv Hetil; 2009 Oct; 150(41):1894-902. PubMed ID: 19801356
[TBL] [Abstract][Full Text] [Related]
11. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans.
Rubin BP; Schuetze SM; Eary JF; Norwood TH; Mirza S; Conrad EU; Bruckner JD
J Clin Oncol; 2002 Sep; 20(17):3586-91. PubMed ID: 12202658
[TBL] [Abstract][Full Text] [Related]
12. Hyalinized collagen in a dermatofibrosarcoma protuberans after treatment with imatinib mesylate.
Thomison J; McCarter M; McClain D; Golitz LE; Goldenberg G
J Cutan Pathol; 2008 Nov; 35(11):1003-6. PubMed ID: 18544062
[TBL] [Abstract][Full Text] [Related]
13. Dermatofibrosarcoma protuberans: recent clinical progress.
McArthur G
Ann Surg Oncol; 2007 Oct; 14(10):2876-86. PubMed ID: 17647063
[TBL] [Abstract][Full Text] [Related]
14. Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans--a case report.
Lemm D; Muegge LO; Hoeffken K; Aklan T; Mentzel T; Thorwarth M; Schultze-Mosgau S
Oral Maxillofac Surg; 2008 Dec; 12(4):209-13. PubMed ID: 18751744
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant imatinib as treatment preceding surgery for vulvar dermatofibrosarcoma protuberans.
Merlo G; Cozzani E; Comandini D; Trave I; Centurioni MG; Franchelli S; Zena M; Vellone VG; Biatta CM; Parodi A
Dermatol Ther; 2021 Mar; 34(2):e14860. PubMed ID: 33559311
[No Abstract] [Full Text] [Related]
16. Molecularly targeted treatment for dermatofibrosarcoma protuberans.
McArthur G
Semin Oncol; 2004 Apr; 31(2 Suppl 6):30-6. PubMed ID: 15176002
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP).
Gooskens SL; Oranje AP; van Adrichem LN; de Waard-van der Spek FB; den Hollander JC; van de Ven CP; van den Heuvel-Eibrink MM
Pediatr Blood Cancer; 2010 Aug; 55(2):369-73. PubMed ID: 20582941
[TBL] [Abstract][Full Text] [Related]
18. Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor.
Sawyers CL
J Clin Oncol; 2002 Sep; 20(17):3568-9. PubMed ID: 12202652
[No Abstract] [Full Text] [Related]
19. Dermatofibrosarcoma protuberans: is mohs surgery truly superior? And the success of tyrosine kinase inhibitors.
Kallini JR; Khachemoune A
J Drugs Dermatol; 2014 Dec; 13(12):1474-7. PubMed ID: 25607791
[TBL] [Abstract][Full Text] [Related]
20. [Good response to treatment with the selective tyrosine-kinase inhibitor imatinib in a patient with metastatic dermatofibrosarcoma protuberans].
Baars A; Pinedo HM
Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2072-6. PubMed ID: 14606355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
